{"id":790,"date":"2017-02-26T19:12:39","date_gmt":"2017-02-26T19:12:39","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?page_id=790"},"modified":"2026-03-17T11:43:56","modified_gmt":"2026-03-17T15:43:56","slug":"lonafarnib-pre-clinical-drug-supply-program","status":"publish","type":"page","link":"https:\/\/www.progeriaresearch.org\/ps\/lonafarnib-pre-clinical-drug-supply-program\/","title":{"rendered":"\u0644\u0648\u0646\u0627\u0641\u0631\u0646\u06cc\u0628 \u062f \u06a9\u0644\u06cc\u0646\u06cc\u06a9\u064a \u062f\u0631\u0645\u0644\u0648 \u0648\u0693\u0627\u0646\u062f\u06d0 \u06a9\u0648\u0644\u0648 \u0628\u0631\u0646\u0627\u0645\u0647"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” disabled_on=”off|off|off” _builder_version=”4.16″ border_width_bottom=”55px” border_color_bottom=”#29327a” locked=”off” global_colors_info=”{}”][et_pb_fullwidth_header _builder_version=”4.18.1″ title_font=”||||||||” title_font_size=”55″ background_color=”#29327a” background_image=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/12\/Aluisio.jpg” background_position=”center_left” custom_padding=”9vw||9vw||true” custom_padding_tablet=”” custom_padding_phone=”|56px||” custom_padding_last_edited=”on|desktop” title_font_size_tablet=”45px” title_font_size_phone=”40px” title_font_size_last_edited=”on|phone” z_index_tablet=”500″ custom_css_main_element=”background-position: center 18% !important;” global_colors_info=”{}”]<\/p>\n

Lonafarnib Pre-clinical<\/h1>\n

Drug Supply Program<\/h1>\n

 <\/p>\n

[\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ use_custom_gutter=”on” gutter_width=”1″ specialty=”on” padding_left_1=”35px” padding_left_2=”35px” padding_2_tablet=”|||0px” padding_2_phone=”|||0px” padding_2_last_edited=”on|desktop” module_class_1=”sidebar-secondary-nav” module_class=”handprint-bg” _builder_version=”4.16″ background_image=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/blue-handprint-only.png” parallax=”on” parallax_method=”off” inner_width=”100%” inner_max_width=”100%” custom_padding=”0|0px|54px|0px|false|false” z_index_tablet=”500″ border_width_top=”10px” border_color_top=”#8fd2ed” use_custom_width=”on” width_unit=”off” custom_width_percent=”100%” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_sidebar area=”et_pb_widget_area_14″ disabled_on=”on|on|off” module_class=”subpage-sidebars” _builder_version=”4.16″ animation_style=”fade” z_index_tablet=”500″ border_width_right=”5px” locked=”off” global_colors_info=”{}”]
\n[\/et_pb_sidebar][\/et_pb_column][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”4.16″ background_color=”#00b2e2″ custom_margin=”41px||” custom_margin_tablet=”0px||” custom_margin_phone=”” custom_margin_last_edited=”on|phone” custom_padding=”39.4375px|20px|0|20px|false|true” animation_style=”slide” animation_direction=”top” animation_intensity_slide=”25%” box_shadow_style=”preset1″ box_shadow_blur=”38px” box_shadow_spread=”-12px” locked=”off” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Lonafarnib Available for Research” _builder_version=”4.18.1″ header_2_line_height=”1.2em” background_layout=”dark” custom_margin=”||35px” custom_padding=”|50px||” custom_padding_tablet=”|50px||50px||true” custom_padding_phone=”” custom_padding_last_edited=”on|desktop” header_font_size_tablet=”” header_font_size_phone=”” header_font_size_last_edited=”on|desktop” header_2_font_size_tablet=”25px” header_2_font_size_phone=”” header_2_font_size_last_edited=”on|tablet” header_4_font_size_tablet=”” header_4_font_size_phone=”19px” header_4_font_size_last_edited=”on|phone” header_4_line_height_tablet=”” header_4_line_height_phone=”1.2em” header_4_line_height_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}”]<\/p>\n

Lonafarnib Available for Research<\/strong><\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=”on|phone” _builder_version=”4.16″ custom_padding=”|35px|0|0px|false|false” custom_padding_tablet=”|35px||35px||true” custom_padding_phone=”” animation_direction=”top” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text disabled_on=”on|on|” admin_label=”Text + Image” _builder_version=”4.18.1″ header_4_line_height=”1.2em” header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}”]<\/p>\n

\"\"PRF makes the farnesyltransferase inhibitor, lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of\u00a0 lonafarnib on Progeria.<\/p>\n

It is PRF\u2019s steadfast mission to find better treatments and a cure for children with Progeria. Lonafarnib has been shown to benefit some aspects of the disease clinically, (Gordon et al, PNAS, 2012) as well as increase lifespan, (Gordon et al, Circulation, 2014) (Gordon et al, JAMA, 2018) but it is not curative. As new compounds are identified with the potential to ameliorate HGPS, we anticipate the need to test these compounds in combination with lonafarnib in vitro and in animal models.<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261×300.jpg” align=”center” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” disabled_on=”||on” admin_label=”Image (mobile only)” _builder_version=”4.16″ z_index_tablet=”500″ global_colors_info=”{}”][\/et_pb_image][et_pb_text disabled_on=”off|off|on” admin_label=”Text (mobile only)” _builder_version=”4.18.1″ header_4_line_height=”1.2em” header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}”]<\/p>\n

PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.<\/p>\n

It is PRF\u2019s steadfast mission to find better treatments and a cure for children with Progeria. Lonafarnib has been shown to benefit some aspects of the disease clinically, (Gordon et al, PNAS, 2012)\u00a0as well as influence increased estimated lifespan, (Gordon et al, Circulation, 2014)\u00a0(Gordon et al, JAMA, 2018) but it is not curative. As new compounds are identified with the potential to ameliorate HGPS, we anticipate the need to test these compounds in combination with lonafarnib in vitro and in animal models.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=”on|phone” _builder_version=”4.16″ custom_padding=”|35px|0|0px|false|false” custom_padding_tablet=”|35px||35px||true” custom_padding_phone=”” animation_direction=”top” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text disabled_on=”on|on|” admin_label=”Technical Notes” _builder_version=”4.18.1″ header_4_line_height=”1.2em” header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”]<\/p>\n

Technical Notes<\/strong><\/h4>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/09\/Lonafarnib-solubility.pdf” button_text=”Solubility PDF” admin_label=”Solubility PDF Button” _builder_version=”4.16″ background_layout=”dark” z_index_tablet=”500″ button_text_shadow_horizontal_length_tablet=”0px” button_text_shadow_vertical_length_tablet=”0px” button_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”][\/et_pb_button][et_pb_button button_url=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/09\/Lonafarnib-administration-to-mice.pdf” button_text=”Administration PDF” admin_label=”Admin pdf button” _builder_version=”4.16″ background_layout=”dark” custom_margin=”20px|||” z_index_tablet=”500″ button_text_shadow_horizontal_length_tablet=”0px” button_text_shadow_vertical_length_tablet=”0px” button_text_shadow_blur_strength_tablet=”1px” box_shadow_horizontal_tablet=”0px” box_shadow_vertical_tablet=”0px” box_shadow_blur_tablet=”40px” box_shadow_spread_tablet=”0px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner column_structure=”1_2,1_2″ custom_padding_last_edited=”on|phone” padding_left_right_link_1=”true” padding_left_right_link_2=”true” _builder_version=”4.16″ custom_margin=”39px||” custom_padding=”0|35px|30px|0px|false|false” custom_padding_tablet=”0px|35px||35px” custom_padding_phone=”0px||0px” animation_direction=”right” global_colors_info=”{}”][et_pb_column_inner type=”1_2″ saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|phone” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Ordering Information” _builder_version=”4.27.5″ header_4_line_height=”1.2em” hover_enabled=”0″ header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

Ordering Information<\/b><\/h4>\n

The material is supplied at no cost.\u00a0 Recipient pays for all shipping charges. To receive lonafarnib, please fill out an application and material transfer agreement, and submit to wnorris@brownhealth.org<\/a><\/p>\n

Application and Agreement<\/a><\/p>\n

Material Transfer Agreement for Non-government Institutions**<\/a><\/p>\n

**<\/strong>\u00a0PRF has a policy of\u00a0no changes to our MTA<\/strong>.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][et_pb_column_inner type=”1_2″ saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|20px|30px|20px” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|desktop” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/FTI-graph.jpg” align=”center” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” _builder_version=”4.16″ animation_style=”slide” animation_direction=”right” animation_intensity_slide=”25%” global_colors_info=”{}”]
\n[\/et_pb_image][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner custom_padding_last_edited=”on|phone” padding_left_right_link_1=”true” padding_left_right_link_2=”true” _builder_version=”4.16″ custom_padding=”25px|35px|30px|0px|false|false” custom_padding_tablet=”0px|35px||35px” custom_padding_phone=”0px||0px” animation_style=”slide” animation_direction=”right” animation_intensity_slide=”25%” border_width_top=”10px” border_color_top=”#8fd2ed” border_width_bottom=”10px” border_color_bottom=”#29327a” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ custom_padding=”|||” custom_padding_tablet=”|0px||0px” custom_padding_phone=”||30px” custom_padding_last_edited=”on|phone” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Contacts for Questions and Assistance:” _builder_version=”4.27.2″ header_4_line_height=”1.2em” header_4_font_size_tablet=”” header_4_font_size_phone=”23px” header_4_font_size_last_edited=”on|phone” z_index_tablet=”500″ global_colors_info=”{}”]<\/p>\n

Contacts for Questions and Assistance:<\/strong><\/h4>\n

Principal Investigator: Leslie B. Gordon, MD, PhD;\u00a0lgordon@progeriaresearch.org<\/a><\/p>\n

PRF Cell & Tissue Bank: Wendy Norris; wnorris@brownhealth.org<\/a><\/p>\n

For U.S. Federal Government Institutions or questions, please contact Wendy Norris, Research Study Coordinator, at wnorris@brownhealth.org<\/a>\u00a0or 401 274-1122 x 48063<\/span>.<\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=”1″ module_class=”footer” _builder_version=”4.21.0″ background_color=”#29327a” custom_margin=”-2px|||||” custom_padding=”0|0px|0|0px|false|false” z_index_tablet=”500″ border_width_top=”12px” border_color_top=”#00b2e2″ global_module=”133″ locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_4,1_4,1_2″ make_equal=”on” module_class=” et_pb_row_fullwidth” _builder_version=”4.16″ width=”89%” width_tablet=”80%” width_phone=”” width_last_edited=”on|desktop” max_width=”89%” max_width_tablet=”80%” max_width_phone=”” max_width_last_edited=”on|desktop” z_index_tablet=”500″ make_fullwidth=”on” width_unit=”off” custom_width_percent=”100%” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_cta button_url=”https:\/\/lp.constantcontactpages.com\/sl\/88gWWwz” button_text=”Sign Up Now” admin_label=”Sign Up for Updates” module_class=”sign-btn” _builder_version=”4.27.4″ header_font_size=”25px” background_color=”#29327a” animation_style=”slide” animation_direction=”left” animation_intensity_slide=”25%” link_option_url=”https:\/\/lp.constantcontactpages.com\/sl\/88gWWwz” header_font_size_tablet=”” header_font_size_phone=”30px” header_font_size_last_edited=”on|desktop” z_index_tablet=”500″ border_radii=”on|25px|25px|25px|25px” global_colors_info=”{}” button_bg_color__hover_enabled=”on” button_bg_color__hover=”#8fd2ed” button_border_color__hover_enabled=”on”]<\/p>\n

Sign Up<\/h2>\n

for Our<\/h2>\n

Updates!<\/h2>\n

[\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_cta button_url=”https:\/\/progeriaresearch.donorsupport.co\/-\/XZHJVWZR” button_text=”Donate Now” admin_label=”Together, we will find the cure!” module_class=”sign-btn” _builder_version=”4.16″ header_font_size=”25px” background_color=”#29327a” animation_style=”slide” animation_direction=”left” animation_intensity_slide=”25%” header_font_size_tablet=”” header_font_size_phone=”30px” header_font_size_last_edited=”on|desktop” body_font_size_tablet=”” body_font_size_phone=”” body_font_size_last_edited=”on|desktop” z_index_tablet=”500″ border_radii=”on|25px|25px|25px|25px” global_colors_info=”{}” button_bg_color__hover_enabled=”on” button_bg_color__hover=”#8fd2ed” button_border_color__hover_enabled=”on”]<\/p>\n

Together, we<\/h2>\n

WILL<\/em><\/h2>\n

find the cure!<\/h2>\n

[\/et_pb_cta][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2026\/03\/2026-footer-image-copy.png” title_text=”2026 footer image copy” _builder_version=”4.27.5″ _module_preset=”default” custom_margin=”35px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” disabled_on=”off|off|off” _builder_version=”4.16″ border_width_bottom=”55px” border_color_bottom=”#29327a” locked=”off” global_colors_info=”{}”][et_pb_fullwidth_header _builder_version=”4.18.1″ title_font=”||||||||” title_font_size=”55″ background_color=”#29327a” background_image=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/12\/Aluisio.jpg” background_position=”center_left” custom_padding=”9vw||9vw||true” custom_padding_tablet=”” custom_padding_phone=”|56px||” custom_padding_last_edited=”on|desktop” title_font_size_tablet=”45px” title_font_size_phone=”40px” title_font_size_last_edited=”on|phone” z_index_tablet=”500″ custom_css_main_element=”background-position: center 18% !important;” global_colors_info=”{}”] Lonafarnib Pre-clinical Drug Supply Program   [\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ use_custom_gutter=”on” gutter_width=”1″ specialty=”on” padding_left_1=”35px” padding_left_2=”35px” padding_2_tablet=”|||0px” padding_2_phone=”|||0px” padding_2_last_edited=”on|desktop” module_class_1=”sidebar-secondary-nav” module_class=”handprint-bg” _builder_version=”4.16″ background_image=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/blue-handprint-only.png” parallax=”on” parallax_method=”off” inner_width=”100%” inner_max_width=”100%” custom_padding=”0|0px|54px|0px|false|false” z_index_tablet=”500″ border_width_top=”10px” […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\t\t\t\t[vc_row][vc_column][vc_custom_heading text=\"Lonafarnib Pre-clinical Drug Supply Program\" font_container=\"tag:h1|text_align:center\" use_theme_fonts=\"yes\"][vc_column_text]July 2015: Lonafarnib Now Available for Research<\/strong>\r\n\r\nPRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\r\n\r\nIt is PRF's steadfast mission to find better treatments and a cure for children with Progeria. Lonafarnib has been shown to benefit some aspects of the disease clinically, (Gordon et al, PNAS, 2012)\u00a0as well as influence increased estimated lifespan, (Gordon et al, Circulation, 2014)\u00a0but it is not curative. As new compounds are identified with the potential to ameliorate HGPS, we anticipate the need to test these compounds in combination with lonafarnib in vitro and in animal models.\r\n\r\nMany thanks to the pharmaceutical company Merck for making this program possible.<\/strong>\r\n\r\nOrdering Information<\/b>\r\n\r\nThe material is supplied at no cost.\u00a0 Recipient pays for all shipping charges.\r\n\r\nTo receive lonafarnib, please fill out an application and material transfer agreement, and submit to joan_brazier@brown.edu<\/a>\r\n\r\n<\/a>Application and Agreement<\/a>\r\n\r\nMaterial Transfer Agreement for Non-government Institutions<\/a>**\r\n\r\n**<\/strong> PRF has a policy of no changes to our MTA<\/strong>.\r\n\r\n<\/strong>\r\n\r\nContacts for Questions and Assistance:<\/strong>\r\n\r\nPrincipal Investigator: Leslie B. Gordon, MD, PhD; lgordon@progeriaresearch.org<\/a>\r\n\r\nResearch Study Coordinator: Joan Brazier; joan_brazier@brown.edu<\/a>\r\n\r\nFor U.S. Federal Government Institutions or questions, please contact Joan Brazier, Research Study Coordinator, at joan_brazier@brown.edu<\/a> or 401-863-9628.[\/vc_column_text][\/vc_column][\/vc_row]\t\t","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-790","page","type-page","status-publish","hentry"],"yoast_head":"\nLonafarnib drug supply | The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/ps\/lonafarnib-pre-clinical-drug-supply-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lonafarnib drug supply | The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/ps\/lonafarnib-pre-clinical-drug-supply-program\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-17T15:43:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"497\" \/>\n\t<meta property=\"og:image:height\" content=\"572\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/lonafarnib-pre-clinical-drug-supply-program\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/lonafarnib-pre-clinical-drug-supply-program\\\/\",\"name\":\"Lonafarnib drug supply | The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/lonafarnib-pre-clinical-drug-supply-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/lonafarnib-pre-clinical-drug-supply-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\",\"datePublished\":\"2017-02-26T19:12:39+00:00\",\"dateModified\":\"2026-03-17T15:43:56+00:00\",\"description\":\"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/lonafarnib-pre-clinical-drug-supply-program\\\/#breadcrumb\"},\"inLanguage\":\"ps\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.progeriaresearch.org\\\/lonafarnib-pre-clinical-drug-supply-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ps\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/lonafarnib-pre-clinical-drug-supply-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/lonafarnib-pre-clinical-drug-supply-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.progeriaresearch.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lonafarnib Pre-clinical Drug Supply Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ps\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ps\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ProgeriaResearch\\\/\",\"https:\\\/\\\/x.com\\\/Progeria\",\"https:\\\/\\\/www.instagram.com\\\/progeriaresearch\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lonafarnib drug supply | The Progeria Research Foundation","description":"PRF \u062f \u0685\u06cc\u0693\u0646\u06d0 \u067c\u0648\u0644\u0646\u06d0 \u062a\u0647 \u062f farnesyltransferase inhibitor lonafarnib \u0686\u0645\u062a\u0648 \u06a9\u0648\u064a. \u0632\u0645\u0648\u0696 \u0647\u062f\u0641 \u062f \u06a9\u0644\u06cc\u0646\u06cc\u06a9\u064a \u0645\u0637\u0627\u0644\u0639\u0627\u062a\u0648 \u0645\u0644\u0627\u062a\u0693 \u06a9\u0648\u0644 \u062f\u064a \u062a\u0631\u0685\u0648 \u067e\u0647 \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u06d0 \u062f \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u0627\u063a\u06cc\u0632\u06d0 \u0646\u0648\u0631 \u062a\u062d\u0642\u06cc\u0642 \u06a9\u0693\u064a.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/ps\/lonafarnib-pre-clinical-drug-supply-program\/","og_locale":"en_US","og_type":"article","og_title":"Lonafarnib drug supply | The Progeria Research Foundation","og_description":"PRF is making the farnesyltransferase inhibitor lonafarnib available to the research community. Our goal is to support preclinical studies to further investigate the effects of lonafarnib on Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/ps\/lonafarnib-pre-clinical-drug-supply-program\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_modified_time":"2026-03-17T15:43:56+00:00","og_image":[{"width":497,"height":572,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@Progeria","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/","url":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/","name":"Lonafarnib drug supply | The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg","datePublished":"2017-02-26T19:12:39+00:00","dateModified":"2026-03-17T15:43:56+00:00","description":"PRF \u062f \u0685\u06cc\u0693\u0646\u06d0 \u067c\u0648\u0644\u0646\u06d0 \u062a\u0647 \u062f farnesyltransferase inhibitor lonafarnib \u0686\u0645\u062a\u0648 \u06a9\u0648\u064a. \u0632\u0645\u0648\u0696 \u0647\u062f\u0641 \u062f \u06a9\u0644\u06cc\u0646\u06cc\u06a9\u064a \u0645\u0637\u0627\u0644\u0639\u0627\u062a\u0648 \u0645\u0644\u0627\u062a\u0693 \u06a9\u0648\u0644 \u062f\u064a \u062a\u0631\u0685\u0648 \u067e\u0647 \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u06d0 \u062f \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u0627\u063a\u06cc\u0632\u06d0 \u0646\u0648\u0631 \u062a\u062d\u0642\u06cc\u0642 \u06a9\u0693\u064a.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb"},"inLanguage":"ps","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/"]}]},{"@type":"ImageObject","inLanguage":"ps","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/04\/Zoey-at-hospital-JAN-13-2014-1-261x300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/lonafarnib-pre-clinical-drug-supply-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Lonafarnib Pre-clinical Drug Supply Program"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\u062f \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0685\u06cc\u0693\u0646\u06cc\u0632 \u0628\u0646\u0633\u067c","description":"\u062f \u0645\u0627\u0634\u0648\u0645\u0627\u0646\u0648 \u0644\u067e\u0627\u0631\u0647 \u2665 \u062f \u062f\u0631\u0645\u0644\u0646\u06d0 \u0644\u067e\u0627\u0631\u0647","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ps"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\u062f \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0685\u06cc\u0693\u0646\u06cc\u0632 \u0628\u0646\u0633\u067c","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"ps","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/pages\/790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/comments?post=790"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/pages\/790\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/ps\/wp-json\/wp\/v2\/media?parent=790"}],"curies":[{"name":"\u0689\u0628\u0644\u06cc\u0648 \u067e\u064a","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}